Key Highlights
- Net loss was USD 1.2 million, or USD 0.34 per share.
- General and administrative expense rose to USD 1.2 million from USD 0.9 million.
- Cash and cash equivalents were USD 1.4 million, plus USD 0.7 million restricted.
- The Eos SENOLYTIX Merger is anticipated to close by year-end.
Merger Costs Lift the Quarterly Loss
Pulmatrix, Inc. (NASDAQ:PULM) reported a third-quarter net loss of USD 1,213 thousand versus USD 877 thousand. After USD 21 thousand of accrued dividends on Series B convertible preferred stock, the net loss attributable to common stockholders was USD 1,234 thousand, or USD 0.34 per share versus USD 0.24, on 3,652,285 weighted average shares.
General and administrative expense was USD 1,220 thousand versus USD 858 thousand, which the company attributes mainly to merger-related legal and professional services. Research and Development was USD 1 thousand versus USD 8 thousand, with all clinical development on hold while the company works to license or monetize its clinical assets.
The Balance Sheet shows total Assets of USD 2,363 thousand versus USD 4,139 thousand and Accounts Payable of USD 815 thousand versus USD 272 thousand.
Nine-Month Results
For the nine months, net loss was USD 3,421 thousand versus USD 4,234 thousand, with general and administrative expense of USD 3,553 thousand versus USD 4,220 thousand and research and development of USD 6 thousand versus USD 41 thousand. Interest income was USD 30 thousand versus USD 124 thousand, and other income, net, was USD 108 thousand versus an expense of USD 164 thousand.
The net loss attributable to common stockholders for the nine months was USD 3,458 thousand.
The Eos SENOLYTIX Merger
The company describes itself as a "biopharmaceutical company" that has focused on inhaled therapeutic products to prevent and treat migraine and respiratory diseases using its iSPERSE technology. It signed a merger agreement with Eos SENOLYTIX, a private biotechnology company developing peptides for mitochondrial dysfunction in aging-related diseases, on March 26, 2026.
The interim chief executive said the registration statement on Form S-4 became effective and stockholders approved the merger, and that the company anticipates closing by the end of the year. The release states closing is subject to Nasdaq approval of the share listing, completion of the Reverse Stock Split approved on October 26, 2026 and other customary conditions.
Alongside the merger agreement, the company sold Series B convertible preferred stock to an affiliate of Eos for aggregate gross proceeds of USD 1.0 million, and the registration statement was declared effective on September 25, 2026.
Assets and Cash
The release lists PUR3100, an orally inhaled migraine candidate with an accepted IND, PUR1900, an itraconazole formulation being advanced by partner Cipla in India, and PUR1800, a kinase inhibitor for acute exacerbations of COPD. Cash and cash equivalents were USD 1,398 thousand versus USD 4,088 thousand at December 31, 2025, with restricted cash of USD 700 thousand, and total liabilities were USD 1,017 thousand. The company states its cash position is sufficient to fund operations at least through the anticipated closing.
The Patent portfolio for iSPERSE included approximately 143 granted patents, 17 of them U.S.-granted, plus about 47 pending applications at September 30, 2026. Pulmatrix would receive 2% royalties on potential net sales by Cipla outside the United States.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...